Chung, W.-S.; Chen, S.-C.; Ko, T.-M.; Lin, Y.-C.; Lin, S.-H.; Lo, Y.-F.; Tseng, S.-C.; Yu, C.-C.
An Integrative Clinical Model for the Prediction of Pathological Complete Response in Patients with Operable Stage II and Stage III Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy. Cancers 2022, 14, 4170.
https://doi.org/10.3390/cancers14174170
AMA Style
Chung W-S, Chen S-C, Ko T-M, Lin Y-C, Lin S-H, Lo Y-F, Tseng S-C, Yu C-C.
An Integrative Clinical Model for the Prediction of Pathological Complete Response in Patients with Operable Stage II and Stage III Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy. Cancers. 2022; 14(17):4170.
https://doi.org/10.3390/cancers14174170
Chicago/Turabian Style
Chung, Wai-Shan, Shin-Cheh Chen, Tai-Ming Ko, Yung-Chang Lin, Sheng-Hsuan Lin, Yung-Feng Lo, Shu-Chi Tseng, and Chi-Chang Yu.
2022. "An Integrative Clinical Model for the Prediction of Pathological Complete Response in Patients with Operable Stage II and Stage III Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy" Cancers 14, no. 17: 4170.
https://doi.org/10.3390/cancers14174170
APA Style
Chung, W.-S., Chen, S.-C., Ko, T.-M., Lin, Y.-C., Lin, S.-H., Lo, Y.-F., Tseng, S.-C., & Yu, C.-C.
(2022). An Integrative Clinical Model for the Prediction of Pathological Complete Response in Patients with Operable Stage II and Stage III Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy. Cancers, 14(17), 4170.
https://doi.org/10.3390/cancers14174170
